Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01015560 · ClinicalTrials.gov registry record · Phase 2

S0916, MLN1202 in Treating Patients With Bone Metastases

A Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target
20
Study locations

NCT01015560 is a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 44 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01015560, a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works in treating patients with bone metastases.

Conditions Studied

Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific

Interventions

  • OTHER laboratory biomarker analysis
  • GENETIC polymorphism analysis
  • DRUG anti-CCR2 monoclonal antibody MLN1202

Study Locations (20)

Kansas

  • Cancer Center of Kansas, PA - Chanute - Chanute
  • Cancer Center of Kansas, PA - Dodge City - Dodge City
  • Cancer Center of Kansas, PA - El Dorado - El Dorado
  • Cancer Center of Kansas - Fort Scott - Fort Scott
  • Cancer Center of Kansas-Independence - Independence
  • Cancer Center of Kansas, PA - Kingman - Kingman
  • Lawrence Memorial Hospital - Lawrence
  • Cancer Center of Kansas, PA - Liberal - Liberal
  • Cancer Center of Kansas, PA - Newton - Newton
  • Cancer Center of Kansas, PA - Parsons - Parsons
  • Cancer Center of Kansas, PA - Pratt - Pratt
  • Cancer Center of Kansas, PA - Salina - Salina
  • Cancer Center of Kansas, PA - Wellington - Wellington
  • Associates in Womens Health, PA - North Review - Wichita
  • Cancer Center of Kansas, PA - Medical Arts Tower - Wichita

California

  • Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles

Indiana

  • St. Francis Hospital and Health Centers - Beech Grove Campus - Beech Grove
  • Reid Hospital & Health Care Services - Richmond

Illinois

  • Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2010-03
Est. Completion 2012-12
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01015560

The ClinicalTrials.gov registry entry for NCT01015560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (90% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT01015560 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Kansas, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT01015560 about?

NCT01015560 is a clinical study titled "S0916, MLN1202 in Treating Patients With Bone Metastases". RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works i...

What is the current status of trial NCT01015560?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2010-03. Estimated completion is 2012-12.

What conditions does trial NCT01015560 study?

This clinical trial studies the following conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT01015560?

The interventions under investigation include: laboratory biomarker analysis (OTHER), polymorphism analysis (GENETIC), anti-CCR2 monoclonal antibody MLN1202 (DRUG).

Who is sponsoring clinical trial NCT01015560?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01015560 being conducted?

This trial has 20 study locations across California, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Cancer

All registered trials for this condition

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.